Get the Stockscreener App
36.26
1.94%
0.69
Maze Therapeutics Inc stock is traded at $36.26, with a volume of 398.21K.
It is up +1.94% in the last 24 hours and up +22.83% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$35.57
Open:
$35
24h Volume:
398.21K
Relative Volume:
0.74
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.47%
1M Performance:
+22.83%
6M Performance:
+244.68%
1Y Performance:
+0.00%
1-Day Range:
$34.44
$36.99
1-Week Range:
$31.47
$37.23
52-Week Range:
$6.71
$37.23
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
36.26 | 1.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Is Maze Therapeutics Inc. stock recession proofJuly 2025 PostEarnings & Safe Capital Investment Plans - newser.com
Maze Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Heatmap analysis for Maze Therapeutics Inc. and competitorsLong Setup & Consistent Income Trade Ideas - newser.com
Will Maze Therapeutics Inc. stock deliver consistent dividendsStock Surge & AI Based Buy and Sell Signals - newser.com
Applying chart zones and confluence areas to Maze Therapeutics Inc.Entry Point & Long-Term Safe Return Strategies - newser.com
Can you recover from losses in Maze Therapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Is Maze Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
Will Maze Therapeutics Inc. outperform the marketOptions Play & High Win Rate Trade Tips - newser.com
How institutional buying supports Maze Therapeutics Inc. stock2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Is Maze Therapeutics Inc. stock oversold or undervaluedJuly 2025 Setups & Weekly Watchlist for Hot Stocks - newser.com
Regression analysis insights on Maze Therapeutics Inc. performanceMarket Risk Report & Safe Entry Momentum Tips - newser.com
Analyzing Maze Therapeutics Inc. with multi timeframe charts2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Raymond James initiates Maze Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):